Muhammad Alam, MD
Nephrology · Shelby, NCNPI 1194731224
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.2% of the total across 268 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations.
Across 268 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$939
- AstraZeneca$935
- Mallinckrodt Hospital Products Inc.$440
- Bayer$416
- OPKO Pharmaceuticals, LLC$325
- Akebia Therapeutics Inc$324
- plus $2K from 23 others
Across 8 payments — averaging $2070.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$17K
What the payments were for
- Food & beverage$5,22893%
- Education$3797%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 45 | $939 |
| AstraZeneca(2 entities) | 50 | $935 |
| Mallinckrodt Hospital Products Inc. | 19 | $440 |
| Bayer | 19 | $416 |
| OPKO Pharmaceuticals, LLC | 19 | $325 |
| Akebia Therapeutics Inc | 15 | $324 |
| Travere Therapeutics, Inc. | 14 | $312 |
| Amgen(2 entities) | 14 | $312 |
| Calliditas Therapeutics US Inc. | 12 | $301 |
| Mallinckrodt Enterprises LLC | 4 | $152 |
| GSK | 9 | $147 |
| Otsuka America Pharmaceutical, Inc. | 8 | $146 |
| Boehringer Ingelheim | 6 | $122 |
| Lilly USA, LLC | 6 | $97 |
| Novartis | 3 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| Sanofi | 3 | $67 |
| Ultragenyx Pharmaceutical Inc. | 3 | $60 |
| ANI Pharmaceuticals, Inc. | 3 | $59 |
| Ardelyx, Inc. | 2 | $55 |
| Daiichi Sankyo Inc. | 2 | $48 |
| Renalytix AI, Inc. | 2 | $37 |
| Cycle Pharmaceuticals Inc | 1 | $27 |
| Spectrum Pharmaceuticals Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$125
How this compares
$5,607 in reported general payments places this provider in the 80th percentile of 366 nephrology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 50 | $43,490 |
| VeltassaPatiromer Calcium Sorbitex | 15 | $16,790 |
| Sevelamer Carbonate | 60 | $6,782 |
| Calcitriol | 401 | $5,190 |
| Calcium Acetate | 52 | $3,806 |
| Losartan Potassium | 565 | $2,941 |
| ProsolParenteral Amino Acid 20% No.1 | 19 | $2,327 |
| Cinacalcet Hcl | 29 | $2,300 |
| Hydralazine Hcl | 143 | $1,281 |
| Amlodipine Besylate | 263 | $1,261 |
| Lisinopril | 240 | $897 |
| Nifedipine ErNifedipine | 56 | $806 |
| Bumetanide | 53 | $799 |
| Atorvastatin Calcium | 26 | $571 |
| Labetalol Hcl | 20 | $548 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $935 | $43,49050 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $59 | $22424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 366 nephrology providers in North Carolina.
Other nephrology in Shelby
- Gregory GreenwoodWinston-Salem$947K
- Michael EtomiCharlotte$212K
- William KendrickGreenville$125K
- Jason EckelCary$123K
- Raven VooraSanford$111K
- Nam VoAsheville$89K
- Jennifer StoddardPinehurst$77K
- Barry FreedmanWinston Salem$67K
- James McCabeWilmington$56K
- Sammy MoghaziRaleigh$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.